GR3006211T3 - - Google Patents

Info

Publication number
GR3006211T3
GR3006211T3 GR920402021T GR920402021T GR3006211T3 GR 3006211 T3 GR3006211 T3 GR 3006211T3 GR 920402021 T GR920402021 T GR 920402021T GR 920402021 T GR920402021 T GR 920402021T GR 3006211 T3 GR3006211 T3 GR 3006211T3
Authority
GR
Greece
Prior art keywords
drug
conjugate
monoclonal antibody
antitumor drug
antibody conjugate
Prior art date
Application number
GR920402021T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3006211T3 publication Critical patent/GR3006211T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
GR920402021T 1987-11-23 1992-11-12 GR3006211T3 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/124,313 US4952394A (en) 1987-11-23 1987-11-23 Drug-monoclonal antibody conjugates

Publications (1)

Publication Number Publication Date
GR3006211T3 true GR3006211T3 (enExample) 1993-06-21

Family

ID=22414122

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920402021T GR3006211T3 (enExample) 1987-11-23 1992-11-12

Country Status (16)

Country Link
US (1) US4952394A (enExample)
EP (1) EP0317957B1 (enExample)
JP (1) JPH02111731A (enExample)
KR (1) KR910005887B1 (enExample)
AT (1) ATE81986T1 (enExample)
AU (1) AU617380B2 (enExample)
CA (1) CA1303524C (enExample)
DE (1) DE3875700T2 (enExample)
DK (1) DK651088A (enExample)
FI (1) FI885361L (enExample)
GR (1) GR3006211T3 (enExample)
IL (1) IL88428A0 (enExample)
NO (1) NO169958C (enExample)
NZ (1) NZ226955A (enExample)
PT (1) PT89062B (enExample)
ZA (1) ZA886811B (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149782A (en) * 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
US5171563A (en) * 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
US5155210A (en) * 1990-09-11 1992-10-13 Brunswick Corporation Methods of conjugating actinomycin d
WO1992005802A1 (en) * 1990-09-28 1992-04-16 Neorx Corporation Polymeric carriers for release of covalently linked agents
US5776458A (en) * 1990-12-05 1998-07-07 Pharmacia & Upjohn S.P.A. Anthracycline-conjugates
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
AU701529B2 (en) * 1994-04-05 1999-01-28 Purdue Research Foundation NADH oxidase as a target in diagnosis and therapy
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
JP2001503396A (ja) * 1996-10-11 2001-03-13 アルザ コーポレイション 治療用リポソーム組成物および方法
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6652836B2 (en) 1998-10-15 2003-11-25 Fluoroprobe, Inc. Method for viewing tumor tissue located within a body cavity
US6299860B1 (en) * 1998-10-15 2001-10-09 Fluoro Probe, Inc. Method for viewing diseased tissue located within a body cavity
IL146047A0 (en) * 1999-04-23 2002-07-25 Alza Corp Releasable linkage and compositions containing same
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
CN100512879C (zh) 1999-04-23 2009-07-15 阿尔萨公司 用于脂质体中的有可裂解键的缀合物
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
CN1110322C (zh) * 1999-07-21 2003-06-04 中国医学科学院医药生物技术研究所 单克隆抗体Fab'－平阳霉素偶联物及其抗肿瘤作用
AU2001227679A1 (en) * 2000-02-25 2001-09-03 General Atomics Mutant nucleic binding enzymes and use thereof in diagnostic, detection and purification methods
WO2001071352A2 (en) * 2000-03-17 2001-09-27 The Salk Institute For Biological Studies Compositions associated with complex formation
US6610504B1 (en) 2000-04-10 2003-08-26 General Atomics Methods of determining SAM-dependent methyltransferase activity using a mutant SAH hydrolase
CA2408921A1 (en) * 2000-05-10 2001-11-15 Bristol-Myers Squibb Company Modified inosine 5'-monophosphate dehydrogenase polypeptides and uses thereof
WO2002043771A2 (en) 2000-12-01 2002-06-06 Cell Works Inc. Conjugates of glycosylated/galactosylated peptide
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
DE60234094D1 (de) 2001-05-11 2009-12-03 Ludwig Inst For Cancer Res Ltd Spezifische bindungsproteine und ihre verwendung
US7129261B2 (en) * 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
US7053188B2 (en) 2002-02-22 2006-05-30 Purdue Research Foundation Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase
US7384760B2 (en) * 2004-04-30 2008-06-10 General Atomics Methods for assaying inhibitors of S-adenosylhomocysteine (SAH) hydrolase and S-adenosylmethionine (SAM)-dependent methyltransferase
RU2402548C2 (ru) * 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
WO2005112919A2 (en) * 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
US7541330B2 (en) * 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
KR20070053214A (ko) * 2004-08-26 2007-05-23 니콜라스 피라말 인디아 리미티드 신규 생분해성 링커를 함유하는 프로드럭
WO2006089230A2 (en) * 2005-02-18 2006-08-24 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (psma)
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EP1940470B1 (en) * 2005-09-26 2013-04-17 Medarex, Inc. Antibody-drug conjugates and their use
EA015324B1 (ru) 2005-10-26 2011-06-30 Медарекс, Инк. Способы и соединения для получения аналогов сс-1065
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
CA2676244C (en) 2007-01-25 2017-01-17 Kwok-Kin Wong Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
CA2678514A1 (en) * 2007-02-21 2008-08-28 Medarex, Inc. Chemical linkers with single amino acids and conjugates thereof
CN101688229B (zh) 2007-03-15 2013-06-12 路德维格癌症研究所 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
CA2688240A1 (en) 2007-05-24 2008-12-04 The United States Government As Represented By The Department Of Veterans Affairs Intranuclear protein transduction through a nucleoside salvage pathway
CA2696360C (en) 2007-08-14 2018-11-20 Ludwig Institute For Cancer Research Monoclonal antibody targeting the egfr receptor and uses thereof
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
US8463365B2 (en) * 2007-09-19 2013-06-11 Oncofluor, Inc. Method for imaging and treating organs and tissues
MX356295B (es) 2008-05-27 2018-05-22 Genzyme Corp Análogos de péptido de la hormona de estimulación de alfa-melanocito.
WO2010065954A2 (en) 2008-12-05 2010-06-10 Abraxis Bioscience, Llc Sparc binding peptides and uses thereof
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
BRPI1011384A2 (pt) 2009-02-23 2016-03-15 Cytomx Therapeutics Inc pro-proteinas e seus metodos de uso
CA2799608C (en) 2009-05-28 2023-02-28 Richard H. Weisbart Amino acid sequences which enhance peptide conjugate solubility
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
US9540438B2 (en) 2011-01-14 2017-01-10 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
CN106414465B (zh) 2014-02-28 2021-11-16 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
CN107001477A (zh) 2014-11-05 2017-08-01 南洋理工大学 经稳定化且自主的抗体vh结构域
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
AU2017286733B2 (en) 2016-06-15 2020-07-02 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
US12486318B2 (en) 2016-06-15 2025-12-02 Yale University Anti-guanosine antibody as a molecular delivery vehicle
CN116143678A (zh) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
US12304970B2 (en) 2018-02-01 2025-05-20 Yale University Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus
WO2022013613A2 (en) 2020-07-17 2022-01-20 Onena Medicines S.L. Antibodies against lefty proteins
EP4079327A1 (en) * 2021-04-22 2022-10-26 Centaurus Polytherapeutics Payloads for drug-conjugates and their use for treating cancer
US20250163144A1 (en) 2021-07-27 2025-05-22 Novab, Inc. Engineered vlrb antibodies with immune effector functions
WO2023056450A1 (en) 2021-09-30 2023-04-06 Yale University Compositions and methods for the treatment of autosomal dominant polycystic kidney disease and other diseases having upregulated mtor activity
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
JP2025529210A (ja) 2022-09-01 2025-09-04 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
WO2024064752A2 (en) 2022-09-20 2024-03-28 Yale University Compositions of wet adhesives derived from vibrio cholerae biofilm adhesins and methods thereof
WO2024145398A1 (en) 2022-12-27 2024-07-04 Yale University Antibody drug conjugates
EP4655007A1 (en) 2023-01-23 2025-12-03 Yale University Antibody oligonucleotide conjugates
WO2024197302A1 (en) 2023-03-23 2024-09-26 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
JPH0651643B2 (ja) * 1983-01-19 1994-07-06 帝人株式会社 殺細胞性修飾免疫グロブリン及びその製造方法
US4625014A (en) * 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
GB8603537D0 (en) * 1986-02-13 1986-03-19 Parker D Conjugate compound

Also Published As

Publication number Publication date
FI885361A7 (fi) 1989-05-24
AU2582488A (en) 1989-05-25
JPH02111731A (ja) 1990-04-24
PT89062A (pt) 1989-11-30
KR910005887B1 (ko) 1991-08-06
US4952394A (en) 1990-08-28
ATE81986T1 (de) 1992-11-15
NO169958B (no) 1992-05-18
KR890007724A (ko) 1989-07-05
DE3875700D1 (de) 1992-12-10
EP0317957A3 (en) 1989-07-05
EP0317957A2 (en) 1989-05-31
DK651088D0 (da) 1988-11-22
ZA886811B (en) 1989-07-26
NO169958C (no) 1992-08-26
NO885199D0 (no) 1988-11-22
NO885199L (no) 1989-05-24
AU617380B2 (en) 1991-11-28
CA1303524C (en) 1992-06-16
IL88428A0 (en) 1989-06-30
PT89062B (pt) 1993-07-30
DE3875700T2 (de) 1993-03-18
FI885361A0 (fi) 1988-11-18
NZ226955A (en) 1991-11-26
FI885361L (fi) 1989-05-24
DK651088A (da) 1989-05-24
EP0317957B1 (en) 1992-11-04

Similar Documents

Publication Publication Date Title
GR3006211T3 (enExample)
FI883597A7 (fi) Menetelmä sytotoksisten aineiden kasvainsoluihin toimittamiseen käyttökelpoisen vasta-aine-entsyymikonjugaatin valmistamiseksi
IL90990A0 (en) Pharmaceutical and diagnostic compositions containing monoclonal antibodies reactive with cachectin and a cell for the production thereof
GR862316B (en) Emulsion compositions for administation of sparingly water soluble ionizable hydrophobic drugs
PT90049A (pt) Forma de dosagem para administrar um medicamento para terapia humana
ATE269089T1 (de) Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen
DK275488D0 (da) Indolonderivater
GB8629567D0 (en) Therapeutic agents
ATE105484T1 (de) Aminderivate von folsaeure analogen.
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
AU557980B2 (en) Perfluorohydrocarbons as vehicles for drugs
DE3474774D1 (en) Therapeutic compositions for oral use containing stable s-adenosy1-l-methionine salts
ATE80616T1 (de) Prostaglandin e1-derivate und ihre therapeutische anwendung.
DE3881254D1 (de) Pharmazeutische zusammensetzung.
GR3018837T3 (en) Subcutaneous administration of human chorionic gonadotrophin.
ES2051864T3 (es) Un procedimiento para preparar una composicion farmaceutica con actividad anti-cancer.
NZ308024A (en) The reaction product of alkaloids of Chelidonium maius L. with thiophosphoric acid triaziridide is used as radiation treatment medicine
GR3002665T3 (en) Use of nitrophenyl groups for stimulating the capability of incorporation of a drug into the sensitive cells of a host
IT1223327B (it) Composti eterociclici alifatici n sostituiti atti a facilitare il passaggio di sostanze attive attraverso le barrierefisiologiche
ES464595A1 (es) Procedimiento de preparacion de nuevos derivados de fenotia-zina.